Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC

Authors

J M. Varlotto
Y Xie
N. Pennell
K Oettel
C M. Lovly
V Anagnostou
G Srkalovic
N J. Mackler
B A. Faller
Paul O. Thieme, Corewell Health West

Document Type

Conference Proceeding

Publication Date

10-2025

Publication Title

Journal of Thoracic Oncology

Abstract

Consolidation durvalumab improves survival for patients (pts) with unresectable stage 3 nonsmall cell lung cancer (NSCLC) after definitive concurrent chemoradiotherapy (CRT). However, the optimal timing of initiation of immune checkpoint inhibition is unknown. EA5181 tested the hypothesis that starting durvalumab concurrent with CRT and continuing as consolidation would improve overall survival compared to consolidation durvalumab alone.

Volume

20

Issue

10, Suppl 1

First Page

S4

Comments

World Conference on Lung Cancer, Sept. 6-9, 2025, Barcelona, Spain

Last Page

S5

Recommended Citation

Varlotto JM, Xie Y, Pennell N, Oettel K, Lovly CM, Anagnostou V, et al [Thieme PO]. Phase 3 trial of concurrent and consolidative durvalumab vs consolidation durva alone for unresectable stage 3 NSCLC. J Thorac Oncol. 2025;20(10, Suppl 1):S4-S5. doi: 10.1016/j.jtho.2025.09.020.

DOI

10.1016/j.jtho.2025.09.020

ISSN

1556-0864